HCM
CLGN icon

Heights Capital Management’s CollPlant Biotechnologies CLGN Stock Holding History

Heights Capital Management’s Portfolio CLGN Stock Details CLGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,258
Closed -$51.8K – 198
2025
Q3 		$51.8K Sell
19,258
-255,824
-93% -$610K 0.01% 127
2025
Q2 		$377K Buy
+275,082
New +$570K 0.1% 86

Other funds holding CLGN

SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Heights Capital Management's CLGN Position: Q4 2025 in Review

Heights Capital Management sold out of CollPlant Biotechnologies (CLGN) in Q4 2025, closing a stake of 19,258 shares — an estimated $51.8K sold.

Heights Capital Management first reported a position in CLGN in Q2 2025 and held it in 2 quarters. The position peaked at $377K in Q2 2025. 17 funds tracked by Wall St. Rank hold CLGN as of Q4 2025.

  • Heights Capital Management reported no remaining CollPlant Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • Heights Capital Management sold 19,258 CollPlant Biotechnologies shares in Q4 2025, an estimated $51.8K.
  • Heights Capital Management first reported a position in CollPlant Biotechnologies in Q2 2025 and held it in 2 quarters.
  • Heights Capital Management's CollPlant Biotechnologies position peaked at $377K in Q2 2025.
  • 17 funds tracked by Wall St. Rank held CollPlant Biotechnologies as of Q4 2025.

Based on Heights Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.